Q-omics provides the consensus-scored H2AC9P profile across patient tissues and cancer cell-line models. H2AC9P expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, H2AC9P is differentially expressed in 13, with the highest sampling consensus in LUAD. Additionally, H2AC9P RNA expression shows 11,887 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, LUAD, and TGCT as cancer lineages where H2AC9P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for H2AC9P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes H2AC9P survival associations across molecular data types. H2AC9P RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible H2AC9P RNA expression–survival associations across cancer types. High H2AC9P expression shows unfavorable associations in ACC, KIRC, UVM, THYM and BLCA, but favorable associations in SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify ACC as the clearest survival context for H2AC9P RNA expression.
This table summarizes H2AC9P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for H2AC9P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. H2AC9P shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, BLCA, HNSC and BRCA. The LUAD box plot shows higher H2AC9P RNA expression in tumor versus normal tissue (log2 FC = +1.195, t-test p < 0.001).
This table shows molecular features associated with H2AC9P in patient tissues and cancer cell lines. In patient samples, H2AC9P shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
